These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 28418910)
1. Erythropoietin drives breast cancer progression by activation of its receptor EPOR. Chan KK; Matchett KB; Coulter JA; Yuen HF; McCrudden CM; Zhang SD; Irwin GW; Davidson MA; Rülicke T; Schober S; Hengst L; Jaekel H; Platt-Higgins A; Rudland PS; Mills KI; Maxwell P; El-Tanani M; Lappin TR Oncotarget; 2017 Jun; 8(24):38251-38263. PubMed ID: 28418910 [TBL] [Abstract][Full Text] [Related]
2. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation. Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950 [TBL] [Abstract][Full Text] [Related]
3. The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer. Hu W; Zhang Y; Jiang Z; Wang L; Li J; Chen S; Dai N; Si J Tumour Biol; 2016 Aug; 37(8):11523-33. PubMed ID: 27086036 [TBL] [Abstract][Full Text] [Related]
4. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells. Wu P; Zhang N; Wang X; Zhang C; Li T; Ning X; Gong K PLoS One; 2012; 7(9):e45122. PubMed ID: 23028796 [TBL] [Abstract][Full Text] [Related]
5. No erythropoietin-induced growth is observed in non-small cell lung cancer cells. Frille A; Leithner K; Olschewski A; Olschewski H; Wohlkönig C; Hrzenjak A Int J Oncol; 2018 Feb; 52(2):518-526. PubMed ID: 29345289 [TBL] [Abstract][Full Text] [Related]
7. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts. Tankiewicz-Kwedlo A; Hermanowicz J; Surażynski A; Rożkiewicz D; Pryczynicz A; Domaniewski T; Pawlak K; Kemona A; Pawlak D Mol Cell Biochem; 2016 Oct; 421(1-2):1-18. PubMed ID: 27543111 [TBL] [Abstract][Full Text] [Related]
8. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Paragh G; Kumar SM; Rakosy Z; Choi SC; Xu X; Acs G Am J Pathol; 2009 Apr; 174(4):1504-14. PubMed ID: 19264915 [TBL] [Abstract][Full Text] [Related]
9. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997 [TBL] [Abstract][Full Text] [Related]
10. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells. Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856 [TBL] [Abstract][Full Text] [Related]
11. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028 [TBL] [Abstract][Full Text] [Related]
12. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. Miyake M; Goodison S; Lawton A; Zhang G; Gomes-Giacoia E; Rosser CJ J Hematol Oncol; 2013 Sep; 6():65. PubMed ID: 24004818 [TBL] [Abstract][Full Text] [Related]
13. Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Inthal A; Krapf G; Beck D; Joas R; Kauer MO; Orel L; Fuka G; Mann G; Panzer-Grümayer ER Clin Cancer Res; 2008 Nov; 14(22):7196-204. PubMed ID: 19010836 [TBL] [Abstract][Full Text] [Related]
14. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Gewirtz DA; Di X; Walker TD; Sawyer ST Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039 [TBL] [Abstract][Full Text] [Related]
15. Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology. Torregrossa F; Aguennouz M; La Torre D; Sfacteria A; Grasso G World Neurosurg; 2019 Nov; 131():346-355. PubMed ID: 31658577 [TBL] [Abstract][Full Text] [Related]
16. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Dunlop EA; Percy MJ; Boland MP; Maxwell AP; Lappin TR Neurodegener Dis; 2006; 3(1-2):94-100. PubMed ID: 16909043 [TBL] [Abstract][Full Text] [Related]
17. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Um M; Gross AW; Lodish HF Cell Signal; 2007 Mar; 19(3):634-45. PubMed ID: 17045782 [TBL] [Abstract][Full Text] [Related]
18. Erythropoietin promotes hair shaft growth in cultured human hair follicles and modulates hair growth in mice. Kang BM; Shin SH; Kwack MH; Shin H; Oh JW; Kim J; Moon C; Moon C; Kim JC; Kim MK; Sung YK J Dermatol Sci; 2010 Aug; 59(2):86-90. PubMed ID: 20554434 [TBL] [Abstract][Full Text] [Related]
19. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Larsson AM; Jirström K; Fredlund E; Nilsson S; Rydén L; Landberg G; Påhlman S Clin Cancer Res; 2009 Sep; 15(17):5552-9. PubMed ID: 19706814 [TBL] [Abstract][Full Text] [Related]
20. Targeting the erythropoietin receptor on glioma cells reduces tumour growth. Pérès EA; Valable S; Guillamo JS; Marteau L; Bernaudin JF; Roussel S; Lechapt-Zalcman E; Bernaudin M; Petit E Exp Cell Res; 2011 Oct; 317(16):2321-32. PubMed ID: 21749867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]